Aurinia Pharmaceuticals (AUPH) Cash from Financing Activities (2020 - 2026)

Aurinia Pharmaceuticals has reported Cash from Financing Activities for 7 years, with the latest figure at -$53.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 8.81% year-over-year to -$53.7 million; the trailing twelve-month figure through Mar 2026 stood at -$110.5 million (down 32.48% YoY), and the FY2025 full-year result was -$106.1 million, down 116.15% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$53.7 million, down from -$1.9 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $1.6 million in Q1 2023, with the low at -$53.7 million in Q1 2026.
• Historically, Cash from Financing Activities has averaged -$13.2 million across 5 years, with a median of -$4.1 million in 2023.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 304.69% — and 2024, when it sank 1018.3%.
• Aurinia Pharmaceuticals' Cash from Financing Activities stood at $688000.0 in 2022, then plunged by 910.61% to -$5.6 million in 2023, then tumbled by 313.23% to -$23.0 million in 2024, then surged by 91.8% to -$1.9 million in 2025, then tumbled by 2741.98% to -$53.7 million in 2026.
• The last three Cash from Financing Activities figures came in at -$53.7 million (Q1 2026), -$1.9 million (Q4 2025), and -$10.5 million (Q3 2025), per Business Quant data.